Atea Pharmaceuticals (AVIR) investor relations material

Company overview and scientific rationale

• Boston-based biotech leverages a nucleoside platform targeting serious viral diseases, currently advancing bemnifosbuvir for hepatitis C in phase 3 trials.

• Hepatitis C remains a significant global health issue, with over 50 million affected worldwide and rising incidence, especially among younger, medically complex patients.

• The regimen combines bemnifosbuvir and ruzasvir, offering high potency, once-daily dosing, short eight-week treatment, minimal drug-drug interactions, and no food effects.

• Positioned to support global hepatitis C eradication initiatives by 2030 through a test-and-treat model.

Clinical data and trial design

• Phase 2 trial showed 98% cure rates overall and up to 100% in compliant non-cirrhotic patients, with strong efficacy even among those with lower adherence.

• The regimen demonstrated high potency across genotypes, including genotype 3, and significant drug forgiveness.

• Phase 3 trials (CBYOND in North America, C4WRD globally) are enrolling, comparing eight-week regimens to 12-week comparators, with results expected mid-2026 and late 2026.

• FDA and ex-U.S. regulators provided positive feedback, shaping trial design and supporting a broad label for diverse patient populations.

Market opportunity and differentiation

• U.S. market research indicates 76% of high-prescribing physicians are extremely likely to prescribe the asset, with preference driven by potency, short duration, and minimal interactions.

• The regimen is differentiated by no effect from proton pump inhibitors, a key advantage over current competitors.

• Current market dominated by two products with patent protection until 2034; the new combination has IP protection until 2042.

• Patient pool is large and growing, with significant government initiatives and funding aimed at expanding screening and treatment.